Pfizer to test second paxlovid course in patients with COVID rebound
Bloomberg: Rong Xu, professor at the School of Medicine, discussed a new study looking at health records from more than 11,000 people who received Paxlovid, the antiviral therapy that consists of two separate medications packaged together, in “COVID rebound,” characterized by a recurrence of COVID-19 symptoms, or a new positive viral test, after having tested negative.